BioCentury
ARTICLE | Clinical News

AZ's Farxiga plus Onglyza non-inferior to Lantus in Phase IIIb for Type II diabetes

July 6, 2018 4:44 PM UTC

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Farxiga (Forxiga) dapagliflozin plus Onglyza saxagliptin met the primary endpoint of non-inferiority to Lantus insulin glargine in reducing HbA1c from baseline to week 24 in a Phase IIIb trial to treat Type II diabetes (1.7% vs. 1.5%, p=0.118). The non-inferiority margin was 0.3%. Data were presented at the American Diabetes Association meeting in Orlando.

The open-label, international trial enrolled 643 Type II diabetics inadequately controlled on metformin to receive Lantus or once-daily 10 mg oral Farxiga plus once-daily 5 mg oral Onglyza with or without sulfonylurea...